SAT Kartar Shopping Ltd (SATKARTAR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by SAT Kartar Shopping Ltd on NSE and BSE, with an AI summary of each filing.
Sat Kartar Life Limited has informed the Exchange regarding ''Receipt of In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015"'.
Others (Uncategorized) · 04 Nov 2026, 1:16 am
Sat Kartar Life Receives NSE In-Principle Approval for Preferential Warrant Issue Sat Kartar Life Limited received in-principle approval from the National Stock Exchange of India on 3rd Nov'26 under Regulation 28(1) of SEBI LODR Regulations. The approval covers the preferential issue of 5,50,000 fully convertible warrants, convertible into equity shares of face value Rs. 10 each, pursuant to the company's application submitted on 1st Oct'26. The approval remains subject to standard regulatory compliances, statutory clearances, and timely submission of listing applications post-allotment.
Sat Kartar Life Limited has informed the Exchange regarding "Receipt of In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015"
Others (Uncategorized) · 04 Nov 2026, 1:12 am
Sat Kartar Life Secures NSE In-Principle Approval for Preferential Issue Sat Kartar Life Limited received in-principle approval from the National Stock Exchange of India (NSE) on 3rd Nov'26 under Regulation 28(1) of SEBI LODR Regulations. The approval covers the issuance of 5,50,000 fully convertible warrants on a preferential basis, convertible into equity shares of face value Rs. 10 each. Final listing remains subject to statutory clearances, regulatory compliances, and internal trade monitoring controls on proposed allottees under SEBI ICDR regulations prior to allotment.
Sat Kartar Life Limited has informed the Exchange about proposal for Establishment of New hospital-cum-therapy Centre in Lucknow, Uttar Pradesh
Others (Uncategorized) · 02 Nov 2026, 6:32 pm
Sat Kartar Life to Establish New 25-Bed Hospital-cum-Therapy Centre in Lucknow Sat Kartar Life Limited has signed a Letter of Intent to set up a new 25-bed hospital-cum-therapy centre across approximately 9,000 sq. ft. in Lucknow, Uttar Pradesh. The project involves an estimated investment of ₹1 Crore, funded via internal accruals and preferential issue proceeds. The facility is expected to become operational by Feb'27, subject to regulatory approvals. This expansion aims to strengthen the company’s presence in integrated Ayurveda and wellness healthcare services, complementing its existing Ayurveda products business across India.
Sat Kartar Life Limited has informed the Exchange about Transcript
Transcript · 29 Oct 2026, 5:19 pm
Sat Kartar Life Reports Strong H1 FY27 Growth and Hospital Expansion Sat Kartar Life reported H1 FY27 consolidated revenue of INR113.9 crores, up 26.4% YoY, while EBITDA rose 47.7% YoY to INR14.5 crores with margins expanding 180 bps to 12.7%. PAT grew 26.7% YoY to INR9.25 crores. Management targets 30% to 35% FY27 revenue growth, with FY28 revenue guidance intact at INR500 crores (INR150–200 crores from hospitals). The company is expanding to 300 hospital beds in FY27, targeting higher-margin compact units, while US sales are scheduled to commence in Nov'26.
Sat Kartar Life Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on October 23, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 27 Oct 2026, 1:03 am
Sat Kartar Life Shareholders Approve Preferential Issue of Convertible Warrants to Promoters Sat Kartar Life Limited announced that shareholders approved a special resolution to issue fully convertible warrants on a preferential basis to the promoter and promoter group at its EGM held on 23rd Oct'26. According to the scrutinizer's report dated 26th Oct'26, the resolution passed unanimously with 100% of the 9,994,136 polled votes cast in favor, representing a 63.27% voter turnout across the company’s total equity base of 15,795,276 shares. No votes were cast against the proposal, and zero invalid votes were recorded.
Sat Kartar Life Limited has informed the Exchange about Schedule of meet
Intimation · 26 Oct 2026, 11:26 pm
Sat Kartar Life Schedules Analyst and Institutional Investor Meeting Sat Kartar Life Limited has scheduled a virtual group meeting with a group of investors and analysts on Fri, 30th Oct'26 at 11:00 AM IST. Pursuant to Regulation 30 of SEBI LODR Regulations, discussions will be restricted to publicly available information, and no unpublished price sensitive information (UPSI) will be shared during the interaction.
Sat Kartar Life Limited has informed the Exchange about Link of Recording
Audio / Video · 26 Oct 2026, 10:46 pm
Sat Kartar Life Releases Audio Recording for H1 FY27 Earnings Call Sat Kartar Life Limited has made available the audio recording of its earnings conference call held on 26th Oct'26. The call reviewed the company's standalone and consolidated unaudited financial results and operational performance for the half-year ended 30th Sep'26. Investors and analysts can access the complete recording via the web link provided on the company's official domain.
Sat Kartar Life Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 26 Oct 2026, 4:39 pm
Sat Kartar Life Reports Strong H1 FY27 Financial Results Sat Kartar Life Limited reported consolidated revenue from operations of ₹11,387.49 lacs for the half year ended 30th Sep'26, up 26.43% YoY from ₹9,007.11 lacs in the period ended 30th Sep'25. Consolidated net profit rose 26.70% YoY to ₹924.90 lacs versus ₹729.98 lacs, translating to a basic and diluted EPS of ₹5.88 compared to ₹4.64. The company reported zero deviations in the utilization of proceeds raised via its ₹33.80 crore IPO and ₹47.22 crore preferential issue.
Sat Kartar Life Limited has informed the Exchange about Investor Presentation
Investor Presentation · 25 Oct 2026, 4:42 pm
Sat Kartar Life Reports Strong H1 FY27 Growth with 48% EBITDA Surge Sat Kartar Life delivered robust H1 FY27 performance, with operational revenue rising 26.4% YoY to ₹113.9 Cr and EBITDA growing 47.7% YoY to ₹14.5 Cr, expanding EBITDA margin by 180 bps to 12.7%. PAT increased 26.7% YoY to ₹9.2 Cr. The company raised ₹47.22 Cr via equity and warrants at ₹172 per share, led by Lighthouse Canton, maintaining a net debt-free balance sheet with ₹18.7 Cr surplus net cash as of Sep'26. Expansion into Ayurvedic hospitals aims to scale beds to ~300 by FY27 and ~1,000 by FY28.
Sat Kartar Life Limited has informed the Exchange regarding a press release dated October 24, 2026, titled "financial performance for the half year ended September 30, 2026.".
Press Release · 25 Oct 2026, 12:08 am
Sat Kartar Life Reports H1 FY27 Results with 26% Revenue and 48% EBITDA Growth Sat Kartar Life reported H1 FY27 revenue of ₹113.9 Crs, up 26.4% YoY, while EBITDA expanded 47.7% YoY to ₹14.5 Crs with margins improving 180 bps to 12.7%. Profit after tax increased 26.7% YoY to ₹9.2 Crs, and EPS stood at ₹5.88. Operationally, its maiden 30-bed Ayurveda hospital in Delhi achieved operational breakeven in Sep'26. The company secured empanelment across 32 insurers, launched Shilajit nutraceutical exports into the US, and announced hospital network additions in Gurugram and Dehradun funded via IPO proceeds.
Sat Kartar Life Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 25 Oct 2026, 12:01 am
Sat Kartar Life Reports H1 FY27 Financial Results with Steady Revenue Growth Sat Kartar Life Limited reported consolidated revenue from operations of ₹11,387.49 lacs for the half year ended 30th Sep'26, up 26.4% YoY compared to ₹9,007.11 lacs in H1 FY26. Consolidated net profit rose 26.7% YoY to ₹924.90 lacs from ₹729.98 lacs, with basic and diluted EPS improving to ₹5.88 versus ₹4.64. On a standalone basis, revenue reached ₹10,646.91 lacs and PAT stood at ₹949.37 lacs. The company reported no deviations in the utilization of its ₹33.80 crore IPO proceeds or ₹47.22 crore preferential issue funds.
Sat Kartar Life Limited has informed the exchange regarding the Monitoring Agency Report for the half year ended on September 30, 2026, issued by CARE Ratings Limited Monitoring Agency, in respect of utilization of proceeds of the IPO of the Company.
Others (Uncategorized) · 24 Oct 2026, 11:18 pm
CARE Ratings Releases Monitoring Agency Report for Sat Kartar Life Sat Kartar Life Limited submitted its Monitoring Agency Report issued by CARE Ratings Limited for the half-year ended 30th Sep'26, covering IPO proceeds of Rs 33.80 crore. As of 30th Sep'26, total cumulative utilization stood at Rs 25.82 crore, leaving Rs 7.98 crore unutilized. During H1FY27, the company deployed Rs 3.49 crore across marketing (Rs 1.30 crore), acquiring a 24% stake in Plantomed Neutraceuticals (Rs 1.20 crore), technology (Rs 0.52 crore), and Ayurvedic hospitals (Rs 0.47 crore), with no reported deviations from revised objects.
Sat Kartar Life Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on October 23, 2026
Annual General Meeting · 24 Oct 2026, 2:11 am
Sat Kartar Life EGM Transacts Preferential Issue of Convertible Warrants Sat Kartar Life Limited conducted its Extra-ordinary General Meeting on 23rd Oct'26 with 25 shareholders attending via VC, representing 1,01,43,846 equity shares (64.22% total shareholding). The key agenda item transacted was a Special Resolution for the issuance of fully convertible warrants on a preferential basis to the promoter/promoter group category to support corporate fund-raising. Remote e-voting concluded on 22nd Oct'26, with post-meeting e-voting finalizing the proceedings. Formal voting results will be disseminated to the NSE and CDSL within two working days.
Sat Kartar Life Limited has informed the Exchange about proposal to establish a New Day Care Therapy Centre in Gurugram, Haryana.
Others (Uncategorized) · 24 Oct 2026, 1:01 am
Sat Kartar Life to Establish Day Care Therapy Centre in Gurugram Sat Kartar Life Limited announced plans to establish a new Day Care Therapy Centre for therapy and OPD services in Gurugram, Haryana. Spanning approximately 1,050 sq. ft. at V Club, Vipul World, Sector 48, the facility is slated to become operational by Nov'26, subject to approvals. The project requires an investment of approximately ₹15 Lacs, financed through IPO funds and internal accruals, aimed at expanding the company's Ayurveda and wellness healthcare network. Additionally, an existing 15-bed Gurugram hospital is in final preparation stages.
Sat Kartar Life Limited has informed the Exchange about the proposal for Establishment of New hospital-cum-therapy Centre in Amritsar, Punjab.
Others (Uncategorized) · 23 Oct 2026, 1:05 am
Sat Kartar Life to Establish ₹1.5 Crore Ayurvedic Hospital in Amritsar Sat Kartar Life Limited has approved the establishment of a new hospital-cum-therapy centre in Amritsar, Punjab, covering approximately 13,000 sq. ft. with a proposed capacity of 30 beds. The project involves an estimated investment of ₹1.5 crore, which will be financed through IPO funds. Aimed at capturing growth potential in Ayurveda-based therapies and expanding its wellness healthcare network, the facility is targeted to become operational by 31st Mar'27, subject to necessary statutory and regulatory approvals.
Sat Kartar Life Limited has informed the Exchange about Schedule of meet
Intimation · 26 Oct 2026, 12:00 pm
Sat Kartar Life Schedules H1 FY27 Earnings Call for 26th Oct'26 Sat Kartar Life Limited will host an earnings conference call for investors and analysts on 26th Oct'26 at 12:00 PM IST. The management, represented by Founder & COO Manprit Singh Chadha, will discuss the company's operational performance and unaudited financial results for the half year ended 30th Sep'26 (H1 FY27).
SAT KARTAR LIFE LIMITED has informed the Exchange about Board Meeting to be held on 24-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 24 Oct 2026, 5:30 am
Sat Kartar Life Board to Consider Half-Yearly Results on 24th Oct'26 Sat Kartar Life Limited has informed the exchange that its Board of Directors is scheduled to meet on 24th Oct'26. The board will inter-alia consider and approve the company's standalone and consolidated unaudited financial results for the half-year ended Sep'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 24 Oct 2026, 5:30 am
Sat Kartar Life Board to Consider Half-Year Financial Results on 24th Oct'26 Sat Kartar Life Limited has scheduled a Board of Directors meeting on 24th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the half year ended 30th Sep'26. Additionally, the trading window for dealing in company securities has been closed for all designated persons, directors, key managerial personnel, promoters, and their immediate relatives starting 1st Oct'26, and will reopen 48 hours post the formal announcement of the financial results.
Sat Kartar Life Limited has informed the Exchange regarding Corrigendum to Notice of Extra Ordinary General Meeting scheduled to be held on October 23, 2026
Extra Ordinary General Meeting · 16 Oct 2026, 1:16 am
Sat Kartar Life Issues EGM Notice Corrigendum for Preferential Warrants Sat Kartar Life Limited issued a corrigendum to its 23rd Oct'26 EGM notice following NSE observations regarding its proposed preferential issue of 5,50,000 convertible warrants to promoters. The revisions account for 1,39,600 outstanding ESOPs and 26,95,200 previously allotted warrants on a fully diluted base of 1,91,80,076 shares. Consequently, promoter holding will shift from 63.45% (1,00,21,556 shares) pre-issue to 55.12% (1,05,71,556 shares) post-issue, with public shareholding rising to 44.88%. The issue entails no change in company management or control.
Sat Kartar Life Limited has informed the exchange regarding Non-Applicability of Regulation 27(2) of the Securities Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th September, 2026.
Others (Uncategorized) · 14 Oct 2026, 12:40 am
Sat Kartar Life Claims Exemption From SEBI Corporate Governance Reporting For Q2 FY27 Sat Kartar Life Limited informed the exchange on 13th Oct'26 regarding the non-applicability of submitting the Corporate Governance Report under Regulation 27(2) of SEBI LODR Regulations for the quarter ended 30th Sep'26. The company claimed an exemption under Regulation 15(2) of SEBI LODR Regulations, as its equity shares are listed on the NSE SME Platform. Consequently, corporate governance disclosure requirements specified under Regulations 17 to 27 do not apply to the company for the period.
Sat Kartar Life Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on October 23, 2026
Annual General Meeting · 01 Oct 2026, 11:25 pm
Sat Kartar Life Proposes ₹9.46 Crore Preferential Warrant Issue to Promoters Sat Kartar Life Limited has scheduled an Extraordinary General Meeting on 23rd Oct'26 to approve the issuance of up to 5,50,000 fully convertible warrants on a preferential basis to promoters and promoter group entities at ₹172 per warrant, representing an 18.20% premium over the floor price of ₹145.51. The ₹9.46 crore fundraising requires 25% upfront subscription, with the remainder payable within 18 months upon conversion. Proceeds are allocated toward healthcare infrastructure expansion (₹6.62 crore) and technology, branding, and market development (₹2.84 crore).
Sat Kartar Life Limited has informed the Exchange regarding Issuance of the Convertible Warrants by way of Preferential Issue
Others (Uncategorized) · 30 Sept 2026, 5:40 pm
Sat Kartar Life Board Approves ₹9.46 Crore Preferential Warrant Issue Sat Kartar Life Limited's board approved issuing up to 5,50,000 convertible warrants at ₹172 per warrant to promoters, raising up to ₹9.46 crore. The issue price stands ~18.20% above the SEBI floor price of ₹145.51. Payable 25% upfront with an 18-month conversion tenor, proceeds will fund expansions in Ayurveda and hospital-based healthcare. Following full conversion, promoter holding will rise from 54.20% to 55.52%. An EGM is scheduled on 23rd Oct'26 with the record date set for 16th Oct'26.
Sat Kartar Life Limited has informed the Exchange regarding Outcome of Board Meeting held on September 30, 2026.
Outcome · 30 Sept 2026, 5:18 pm
Sat Kartar Life Board Approves ₹9.46 Crore Preferential Warrant Issue Sat Kartar Life's Board approved the preferential issuance of up to 5,50,000 convertible warrants at ₹172 per warrant, raising up to ₹9.46 crore from promoters. The issue price represents an 18.20% premium over the SEBI floor price of ₹145.51. Post-conversion, promoter and promoter group shareholding will increase from 54.20% to 55.52%. Warrants carry an 18-month tenure with 25% payable upon subscription. The capital will support its integrated healthcare expansion. An EGM for shareholder approval is scheduled for 23rd Oct'26, with 16th Oct'26 set as the voting cut-off.
SAT KARTAR LIFE LIMITED has informed the Exchange about Board Meeting to be held on 30-Sep-2026 to consider Fund raising.
Intimation · 26 Sept 2026, 2:02 am
Sat Kartar Life Schedules Board Meeting on 30th Sep'26 for Fund Raising Sat Kartar Life Limited has informed the exchange that a meeting of its Board of Directors is scheduled to be held on 30th Sep'26 to evaluate and consider various fund-raising options, subject to regulatory and shareholder approvals as may be required.
To consider Fund Raising
Intimation · 26 Sept 2026, 1:39 am
Sat Kartar Life Board to Consider Fund Raising on 30th Sep'26 Sat Kartar Life Limited has scheduled a Board of Directors meeting on 30th Sep'26 to consider and approve a fund-raising proposal. The capital raise is planned via the issuance of equity shares and/or convertible warrants on a preferential issue basis or through other permissible modes in one or more tranches, subject to regulatory approvals. Consequently, the trading window for dealing in the company's securities is closed for designated persons and their immediate relatives from 25th Sep'26 until 48 hours post-meeting conclusion.